On March 21, the National Medical Insurance Administration issued the “Notice on Effectively Doing a Good Job in the Current Epidemic Prevention and Control of Medical Insurance”. The notice clarifies that the new crown treatment drugs included in the scope of medical insurance payment should be adjusted in a timely manner, and the newly added naimatevir tablets/ritonavir tablets in the “New Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial Version 9)” shall be adjusted by medical institutions in accordance with The company communicates with relevant departments to purchase at a consistent price, and the medical insurance department pays according to regulations.
On March 16, the new coronavirus treatment drug PAXLOVID arrived at Shanghai Pudong Airport. Image courtesy of General Technology Chinese Medicine.
On February 11, the State Food and Drug Administration approved the import registration of PAXLOVID with conditions. According to Pfizer’s official website, PAXLOVID is an oral small-molecule novel coronavirus treatment drug, for the treatment of adults with mild to moderate novel coronavirus pneumonia with high risk factors for progression to severe disease, such as advanced age, chronic kidney disease, Patients with severe risk factors such as diabetes, cardiovascular disease, and chronic lung disease. According to the results of Pfizer’s investigational novel COVID-19 oral antiviral drug candidate, PAXLOVID, announced in 2021, an interim analysis showed that the drug reduced the risk of hospitalization and death in high-risk COVID-19 patients by 89%.
Up to now, the domestic price of the drug has not been publicly disclosed. According to public information, the price of Pfizer’s PAXLOVID in the United States is: for a 5-day course of treatment, the US government needs to pay about 530 US dollars (about 3367 yuan).
On March 20, according to the official WeChat account of Sinopharm, on March 19, the first batch of the new coronavirus treatment drug PAXLOVID, which Sinopharm cooperated with Pfizer, has been delivered to Sinopharm Daxing Logistics In the center, all goods have been closed-loop management of the whole process of transportation in accordance with the relevant import and export requirements for epidemic prevention, and have completed inspection and storage and other related work.
China Medicine said that at present, the company has received an order to urgently need urgent protection of medicines, and all medicines are being quickly shipped to the front line of the country’s anti-epidemic.
